Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 26, 2025•about 1 year ago

Contract Type

contract

DurhamBiotechnologyHealth CareMedical Device

Description

Humacyte, Inc. has announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $2.00 per share, with expected aggregate gross proceeds of $50 million. The net proceeds will be used to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates in Humacyte’s pipeline, and for working capital and general corporate purposes.

Company Information

Company

Humacyte

Location

Durham, North Carolina, United States

About

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Humacyte's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months